On Monday, Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) was -1.58% drop from the session before settling in for the closing price of $28.49. A 52-week range for KNSA has been $17.38 – $30.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 27.38%. When this article was written, the company’s average yearly earnings per share was at 220.74%. With a float of $40.47 million, this company’s outstanding shares have now reached $42.16 million.
The extent of productivity of a business whose workforce counts for 315 workers is very important to gauge. In terms of profitability, gross margin is 81.02%, operating margin of -3.28%, and the pretax margin is -1.31%.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Kiniksa Pharmaceuticals International Plc stocks. The insider ownership of Kiniksa Pharmaceuticals International Plc is 44.54%, while institutional ownership is 55.17%. The most recent insider transaction that took place on Jun 16 ’25, was worth 489,244. In this transaction CHIEF OPERATING OFFICER of this company sold 17,300 shares at a rate of $28.28, taking the stock ownership to the 61,563 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 17,300 for $28.28, making the entire transaction worth $489,171.
Kiniksa Pharmaceuticals International Plc (KNSA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 220.74% per share during the next fiscal year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
You can see what Kiniksa Pharmaceuticals International Plc (KNSA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.25. Likewise, its price to free cash flow for the trailing twelve months is 46.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit 0.19 in the next quarter and is forecasted to reach 1.27 in one year’s time.
Technical Analysis of Kiniksa Pharmaceuticals International Plc (KNSA)
The latest stats from [Kiniksa Pharmaceuticals International Plc, KNSA] show that its last 5-days average volume of 2.22 million was superior to 0.7 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 48.71%.
During the past 100 days, Kiniksa Pharmaceuticals International Plc’s (KNSA) raw stochastic average was set at 78.92%, which indicates a significant increase from 36.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.56% in the past 14 days, which was lower than the 50.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.51, while its 200-day Moving Average is $23.10. Now, the first resistance to watch is $28.63. This is followed by the second major resistance level at $29.22. The third major resistance level sits at $29.58. If the price goes on to break the first support level at $27.68, it is likely to go to the next support level at $27.32. The third support level lies at $26.73 if the price breaches the second support level.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Key Stats
There are 72,971K outstanding shares of the company, which has a market capitalization of 2.05 billion. As of now, sales total 423,240 K while income totals -43,190 K. Its latest quarter income was 137,790 K while its last quarter net income were 8,540 K.
